USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Aastrom Biosciences, Inc.
City: Ann Arbor
State: MI
Zip+4: 48105
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (734) 930-5555

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,761,886.00 17
SBIR Phase II $4,270,825.00 7

Award List:

Clonal Hematopoietic Progenitor Cell Assay

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Manfred R. Koller
Award Amount: $50,000.00
Abstract:
Hematopoiesis, the regulated production of mature blood cells, is a complex scheme of multilineage differentiation which occurs mainly in the bone marrow of adult mammals. Mature cells are continuously produced from progenitor (or precursor) cells. Consequently, assays which detect these progenitor… More

Hematopoietic Cell Expansion System

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas R. Armstrong
Award Amount: $50,000.00

Hematopoietic Cell Expansion System

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Douglas R. Armstrong
Award Amount: $520,371.00
Abstract:
Bone marrow transplant (BMT) is an extraordinarily rapidly growing field, and the number of transplants in the U. S. is expected to grow from a current rate of 15,000 per year to over 100,000 per year by 1995. This rapid expansion is due to the diversity in the types of bone marrow transplantation… More

Expansion of Stem Cells From CD34-Enriched Populations

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Manfred Koller
Award Amount: $70,948.00
Abstract:
In vitro expansion of hematopoietic cells finds many applications in the clinic. This technique hasexpanding CD34+ cells for transplantation/re infusion, although most of the technology has consistedcultures in which there is variable CFUGM expansions and failure to maintain LTC IC (long term… More

EXPANSION OF HUMAN UMBILICAL CORD BLOOD STEM CELLS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Smith, alan k
Award Amount: $98,102.00

Expansion of Stem Cells From CD34-Enriched Populations

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator: Manfred Koller
Award Amount: $736,510.00
Abstract:
In vitro expansion of hematopoietic cells finds many applications in the clinic. This technique hasexpanding CD34+ cells for transplantation/re infusion, although most of the technology has consistedcultures in which there is variable CFUGM expansions and failure to maintain LTC IC (long term… More

CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Smith, Douglas M
Award Amount: $98,825.00

EXPANSION OF HUMAN UMBILICAL CORD BLOOD STEM CELLS

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator: Smith, alan k
Award Amount: $769,484.00

EXPANSION AND GENETIC TRANSDUCTION OF EBV-SPECIFIC CTLS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas M. Smith
Award Amount: $99,805.00
Abstract:
Not Available Differential absorption lidar (DIAL) systems have become extremely useful tools for remote sensing of atmospheric constituents. Physical Sciences Inc. proposes to develop a compact, lightweight, quantum cascade (QC) laser-based DIAL transceiver for remote sensing of airborne chemical… More

MEGAKARYOCYTE EXPANSION FROM MOBILIZED PERIPHERAL BLOOD

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan K. Smith
Award Amount: $99,839.00

STROMAL EFFECTS ON UMBILICAL CORD BLOOD EXPANSION

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan K. Smith
Award Amount: $105,456.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kristin L. Goltry
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kristin L. Goltry
Award Amount: $368,781.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas M. Smith
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Douglas M. Smith
Award Amount: $334,347.00

Clinical Human Cell Production System for Broad Use

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brian S. Hampson
Award Amount: $101,452.00
Abstract:
DESCRIPTION (provided by applicant): As a result of growing evidence of their therapeutic potential in cancer, infectious diseases, and tissue repair, there is an enormous increase in the research and discovery of cell-based medical treatments that require cultured cells. A large unmet need exists… More

Enhanced Tumor Antigen Priming of Dendritic Cell Vaccine

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas M. Smith
Award Amount: $101,262.00
Abstract:
DESCRIPTION (provided by the applicant): Dendritic cells have been shown to initiate, regulate, and direct cytolytic T-cell-mediated immune responses against tumor antigens in human patients. Recent clincal trials have demonstrated induction of clinically significant immune responses against… More

Automated Perfused Culture Process for Adult Stem Cells

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kristin L. Goltry
Award Amount: $442,555.00
Abstract:
DESCRIPTION (provided by applicant): Adherent mesenchymal cell populations derived from bone marrow (BM) have the capability of differentiating into multiple cell lineages in vitro and in vivo. The potential use of these populations, referred to as marrow stromal cells (MSC), in clinical… More

Clinical-scale Production of Osteoprogenitor Cells

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kristin L. Goltry
Award Amount: $110,062.00
Abstract:
DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Mixtures of marrow stromal cells (MSC) and carrier matrices are known to augment bone repair. Increasing the number of MSC through ex vivo… More

Automated Large-Scale Production of Endothelial Cells

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kristin L. Goltry
Award Amount: $99,840.00
Abstract:
DESCRIPTION (provided by applicant): Treatment of ischemia by administration of bone marrow (BM)-derived endothelial progenitor cells (EPC) or ex vivo expanded EPC populations has been shown to enhance vascular regeneration in animal models and in clinical trials. For cell therapy to be practical in… More

Dendritic Cell Subset for Enhanced Cancer Vaccine

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas M. Smith
Award Amount: $109,586.00
Abstract:
DESCRIPTION (provided by applicant): Tumor antigen primed dendritic cells (DCs) are under widespread clinical evaluation for immunotherapy of multiple forms of cancer. Emerging evidence suggests that DCs are fundamental regulators of the immune response leading to potent cell mediated immunity or… More

Bioreactor for Enhanced T-cell Based Therapy of Melanoma

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas M. Smith
Award Amount: $124,154.00
Abstract:
DESCRIPTION (provided by applicant): Malignant melanoma is a significant and deadly form of cancer worldwide. Emerging evidence has shown that melanoma cells express tumor-associated antigens that are specifically recognized by the immune system. Melanoma antigen-specific T-lymphocytes can be… More

Clinical-scale Production of Osteoprogenitor Cells

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kristin L. Goltry
Award Amount: $743,066.00
Abstract:
DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Cells within the bone marrow are known to possess bone regenerative capacity, but they are limited in number. Increasing these osteoprogenitor cell… More

Clinical Human Cell Production System for Broad Use

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Brian S. Hampson
Award Amount: $798,266.00
Abstract:
The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As a result, the motivation to commercialize patient-specific "cell products" is increasing rapidly as… More